Adam Lerner, MD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MD, Yale University School of Medicine



Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Professor
Boston University School of Medicine
Pathology & Laboratory Medicine


Active Staff Privileges
Boston Medical Center
Medicine
Hematology & Medical Oncology Section



A randomized, open-label, phase 3 trial of Brentuximab vedotin (SGN-35) versus physician's choice (Methotrexate or Bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma
08/10/2012 - 08/10/2019 (PI)
Millennium Pharmaceuticals, Inc.

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
02/03/2014 - 02/02/2019 (PI)
Kyowa Hakko Kirin Pharma, Inc.

Research Training in Blood Diseases and Resources
06/01/2014 - 05/31/2018 (Co-PI)
PI: Martin H. Steinberg, MD
NIH/National Heart, Lung, and Blood Inst
5T32HL007501-34

Personnel Agreement for Research Services of Deborah Govan
01/01/2013 - 01/28/2016 (PI)
VA Boston Healthcare System

Research Training in Blood Diseases and Resources
09/19/2008 - 05/31/2014 (PI)
NIH/National Heart, Lung, and Blood Inst
5T32HL007501-31

Access Program with Denileukin diftitox for the treatment of patients currently receiving treatment with commercially available Ontak
11/01/2011 - 10/31/2012 (PI)
Eisai Medical Research Institute, Inc.

A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma
03/27/2006 - 03/26/2008 (PI)
CuraGen Corporation

The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma
11/03/2005 - 11/02/2007 (PI)
Genentech, Inc.

A Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients with Metastatic Malignant Melanoma
12/23/2005 - 12/31/2006 (PI)
Luitpold Pharmaceuticals, Inc.

Open-label, Dose Escalation, Followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with
06/02/2005 - 06/01/2006 (PI)
Genmab Inc.

Showing 10 of 14 results. Show All Results

CRXX-Lerner laboratory CLL Research Collaboration
02/01/2008 - 06/30/2011 (PI)
CombinatorX, Inc.

Using audio to convey mind/body approaches to cancer
06/14/2006 - 03/31/2011 (PI)
Far Reaching Communications NIH
R44 CA86403-02

PDE4 Inhibitors & Glucocorticoids in B-CLL
08/01/2006 - 01/31/2011 (PI)
Memory Pharmaceutical Corp.

Mechanistic Studies of BRC3-induced Anti-estrogen Resistance
01/01/2010 - 12/31/2010 (PI)
Breast Cancer Alliance

Cell Pathways
07/01/2002 - 12/31/2010 (PI)
Cell Pathways Inc

Cyclic AMP - Mediated Apoptosis in Lymphoid Malignancies
07/01/2005 - 06/30/2010 (PI)
NIH-NCI
5 R01 CA106705-05

Tamoxifen Resistance in Breast Cancer
10/31/2002 - 12/31/2009 (PI)
Logica Foundation

Analysis of AND-34 in human breast cancer
07/01/2005 - 06/30/2009 (PI)
NIH-NCI
5 R01 CA114094-04 (A)

Analysis Of And-34
09/01/2001 - 09/30/2005 (PI)
US Army

Apoptosis In Normal And Malign
07/01/2000 - 06/30/2005 (PI)
NIH-NCI
5 R01 CA79838-04 (A)

Showing 10 of 13 results. Show All Results


Yr Title Project-Sub Proj Pubs
2016 Research Training in Blood Diseases and Resources 5T32HL007501-34 74
2014 Research Training in Blood Diseases and Resources 2T32HL007501-32 74
2012 Research Training in Blood Diseases and Resources 5T32HL007501-31 74
2011 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-15-5136 236
2011 Research Training in Blood Diseases and Resources 5T32HL007501-30 74
2010 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-14-6841 236
2010 Research Training in Blood Diseases and Resources 5T32HL007501-29 74
2009 EFFECT OF PHOSPHORYLATION ON INTERACTION OF P130CAS WITH AND-34 5P41RR010888-13-6196 236
2009 Cyclic AMP-mediated apoptosis in lymphoid malignancies 5R01CA106705-05 5
2009 Research Training in Blood Diseases and Resources 5T32HL007501-28 74
Showing 10 of 27 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Sep 01; 40:73-80. PMID: 28867658.
  2. Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2017 Aug 30; 1-8. PMID: 28853310.
  3. Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428; DOI: 10.1016/j.clml.2016.08.009;.
  4. Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC. Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016 Sep; 38:223-32.View Related Profiles. PMID: 27302770; DOI: 10.1016/j.intimp.2016.06.004;.
  5. Dong H, Carlton ME, Lerner A, Epstein PM. Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells. Front Pharmacol. 2015; 6:230. PMID: 26528184; DOI: 10.3389/fphar.2015.00230;.
  6. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237; PMCID: PMC4732431; DOI: 10.3109/10428194.2015.1014360;.
  7. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015 Jan 1; 194(1):101-12.View Related Profiles. PMID: 25416804; PMCID: PMC4333002.
  8. Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar; 168(6):811-9. PMID: 25404094; DOI: 10.1111/bjh.13222;.
  9. Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014; 2:16. PMID: 25279222; DOI: 10.1186/2050-7771-2-16;.
  10. Tapan U, Pestana JB, Lee JC, Lerner A. Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach. Leuk Lymphoma. 2015 Feb; 56(2):505-7. PMID: 24794809; DOI: 10.3109/10428194.2014.919632;.
Showing 10 of 39 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 39 publications over 15 distinct years, with a maximum of 6 publications in 2007

YearPublications
20023
20034
20041
20051
20062
20076
20081
20095
20101
20112
20123
20143
20153
20162
20172
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Breast cancer
cAMP
CLL
Phosphodiesterases
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Lerner's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department